14 HIV/AIDS drugs - Government Sponsorship of Trials and time to Market

[Thiru Balasubramaniam <thiru@cptech.org>]

Interesting facts

Average time from application for patent to US FDA approval
only 4.4 years

Average percent of clinical trials in ACTIS database sponsored
by US government -- 55%.

                    14 HIV/AIDS drugs - Government 
               Sponsorship of Trials and time to Market
                                             
                                                       patent
            clinical trials in ACTIS    %    CRISP     appl
                         gov/non-gov    gov  grants    to NDA

     Nucleoside Analogue Reverse Transcriptase Inhibitors (RT)
Zidovudine (AZT)/Retrovir     314/189   62%  1,462     1.5 yrs
Didanosine (ddI)/Videx        131/59    69%  66        4.2
Zalcitabine (ddC)/Hivid       43/26     62%  6         4.9
Stavudine (d4T)/Zerit         53/56     49%  158       7.5
Lamivudine (3TC)/Epivir       65/54     55%  191       6.8
Abacavir/Ziagen               19/29     40%  2         8.0
     Protease Inhibitors 
Saquinavir/Invirase           25/32     44%  29        5.0
Ritonavir/Norvir              30/28     52%  43        0.9
Indinavir/Crixivan            53/54     50%  91        2.9
Nelfinavir/Viracept           40/41     49%  25        5.7
Amprenavir/Agenerase          14/11     56%  1         5.4
     Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI) 
Nevirapine/Viramune           42/23     65%  151       2.9 
Delavirdine/Rescriptor        20/20     50%  53        3.1
Efavirenz/Sustiva             22/17     56%  1         3.3 

				AVG: 	55%            4.4 yr    

CPT: Thiru Balasubramaniam, Nov 19, 1999